SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : OXIGENE INC. (OXGN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: nigel bates who wrote (250)2/16/2005 4:13:39 AM
From: Nikole Wollerstein  Read Replies (1) of 273
 
"OXiGENE's lead compound Combretastatin A4 Prodrug (CA4P) enhances the anti-tumor activity of Avastin, an anti-angiogenic agent approved for use in the treatment of colorectal cancer."
Just another reason for sell of?

but
breaking with the year long pattern a day
after news release OXGN closed not on 2 days low but on 2 month high.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News